Literature DB >> 31918267

MicroRNA-9 and breast cancer.

Xiaoman Li1, Zhu Zeng2, Jiaer Wang2, Yuanyuan Wu1, Wenxing Chen1, Lufeng Zheng3, Tao Xi3, Aiyun Wang4, Yin Lu5.   

Abstract

Breast cancer is the most common cancer in women worldwide and seriously impairs patients' physical and mental health. Its incidence has been predicted to rise further. Mounting evidence indicates that microRNAs (miRNAs) play key roles in tumorigenesis and development. It is worth noting that miR-9 exerts critical functions in the initiation and progression of breast cancer, and the present research displays opposite roles of miR-9 in breast cancer. This article mainly reviews the roles of miR-9 in breast cancer progression.
Copyright © 2019 The Author(s). Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Breast cancer; Oncogene; Tumor suppressor; Tumorigenesis and development; miR-9

Year:  2019        PMID： 31918267     DOI： 10.1016/j.biopha.2019.109687

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN： 0753-3322            Impact factor:   6.529


  22 in total

1.  LINC01116 Promotes Migration and Invasion of Oral Squamous Cell Carcinoma by Acting as a Competed Endogenous RNA in Regulation of MMP1 Expression.

Authors:  Yukang Ying; Dong Liu; Yue Zhao; Yuan Zhong; Xuhui Xu; Jun Luo; Zhenxing Zhang
Journal:  Comput Math Methods Med       Date:  2022-06-17       Impact factor: 2.809

Review 2.  Extracellular Vesicle Application as a Novel Therapeutic Strategy for Ischemic Stroke.

Authors:  Yiyang Li; Bowen Liu; Ying Chen; Xingping Quan; Yan Han; Ying Zheng; Yonghua Zhao
Journal:  Transl Stroke Res       Date:  2021-05-13       Impact factor: 6.829

3.  Interplay between cyclooxygenase‑2 and microRNAs in cancer (Review).

Authors:  Zexiong Gong; Weiguo Huang; Baiyun Wang; Na Liang; Songkai Long; Wanjun Li; Qier Zhou
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

4.  miR-9-5p as a Regulator of the Androgen Receptor Pathway in Breast Cancer Cell Lines.

Authors:  Erika Bandini; Francesca Fanini; Ivan Vannini; Tania Rossi; Meropi Plousiou; Maria Maddalena Tumedei; Francesco Limarzi; Roberta Maltoni; Francesco Fabbri; Silvana Hrelia; William C S Cho; Muller Fabbri
Journal:  Front Cell Dev Biol       Date:  2020-11-12

Review 5.  Epigenetic Alterations in Triple-Negative Breast Cancer-The Critical Role of Extracellular Matrix.

Authors:  Vasiliki Zolota; Vasiliki Tzelepi; Zoi Piperigkou; Helen Kourea; Efthymia Papakonstantinou; Μaria-Ioanna Argentou; Nikos K Karamanos
Journal:  Cancers (Basel)       Date:  2021-02-09       Impact factor: 6.639

Review 6.  Signaling pathways governing breast cancer stem cells behavior.

Authors:  Kai Song; Maryam Farzaneh
Journal:  Stem Cell Res Ther       Date:  2021-04-16       Impact factor: 6.832

7.  Micro1278 Leads to Tumor Growth Arrest, Enhanced Sensitivity to Oxaliplatin and Vitamin D and Inhibits Metastasis via KIF5B, CYP24A1, and BTG2, Respectively.

Authors:  Weidong Lin; Heng Zou; Jinggang Mo; Chong Jin; Hao Jiang; Chengyang Yu; Zufu Jiang; Yusha Yang; Bin He; Kunpeng Wang
Journal:  Front Oncol       Date:  2021-03-11       Impact factor: 6.244

Review 8.  Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives.

Authors:  Ebrahim Rahmani Moghadam; Hui Li Ang; Sholeh Etehad Asnaf; Amirhossein Zabolian; Hossein Saleki; Mohammad Yavari; Hossein Esmaeili; Ali Zarrabi; Milad Ashrafizadeh; Alan Prem Kumar
Journal:  Biomolecules       Date:  2020-09-27

9.  miR-9-Mediated Inhibition of EFEMP1 Contributes to the Acquisition of Pro-Tumoral Properties in Normal Fibroblasts.

Authors:  Giulia Cosentino; Sandra Romero-Cordoba; Ilaria Plantamura; Alessandra Cataldo; Marilena V Iorio
Journal:  Cells       Date:  2020-09-22       Impact factor: 6.600

10.  Tanshinone IIA attenuates the stemness of breast cancer cells via targeting the miR-125b/STARD13 axis.

Authors:  Xiaoman Li; Qi Jia; Yinyin Zhou; Xuan Jiang; Li Song; Yuanyuan Wu; Aiyun Wang; Wenxing Chen; Shijun Wang; Yin Lu
Journal:  Exp Hematol Oncol       Date:  2022-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.